NCT00689169 - Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2014

Conditions

Lymphoma, Large Cell, Diffuse

Interventions

DRUG

ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)

Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2

PROCEDURE

ASCT

ASCT : D0

DRUG

Rituximab

Rituximab 250 mg/m² :D-21 D-14

Trial Locations (1)

75010

service d'onco hématologie adultes, hôpital Saint Louis, Paris